Company Overview and News

 
Copper Mountain - The Eva Construction May Be Suspended

2018-09-13 seekingalpha
This year Copper Mountain purchased Altona Mining, an Australia-based exploration company owning the Eva copper project.
CPPMF AOH 5711 MIMTF

 
Copper Mountain Mining now dual listed, gets ASX boost following Altona deal

2018-04-10 australianmining.com.au
Canadian company Copper Mountain Mining Corporation (CMMC) is now trading on the Australian Securities Exchange (ASX) following its $93 million acquisition of Altona Mining, first announced last November. The company already trades on the Toronto Stock Exchange (TSX).
OZMLF AOH CPPMF FND OZL

 
Altona gains approval for $93m merger

2018-03-26 businessnews.com.au
Aspiring copper miner Altona Mining is one step closer to a $93 million merger with Canada-based Copper Mountain Mining after Altona shareholders approved the scheme of arrangement today.
AOH

 
A Small-Cap Mining Company That Is Worth Taking A Look At

2018-03-13 seekingalpha
Strong growth prospects from the newly acquired Altona Mining Ltd. This company has a large undeveloped mining site in Queensland, Australia.
CPPMF AOH 5711 MIMTF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...